Multimodal Analgesia TREATMENT OF PAIN Multimodal analgesia combines different classes of medications that have different ( multimodal ) pharmacological mechanisms of action, resulting in additive or synergistic effects to reduce postoperative pain and its sequelae. Such an approach may achieve desired analgesic effects while reducing analgesic dosage and associated side effects. Multimodal pain management often includes utilization of regional analgesic techniques , including local anesthetic wound infusion, epidural/intrathecal analgesia, or single shot/continuous peripheral nerve blockade. Multimodal analgesia is routinely utilized to improve postoperative outcomes. 1. NSAIDs — The addition of nonsteroidal anti-inflammatory drugs (NSAIDs) to systemic opioid analgesia diminishes postoperative pain intensity, reduces opioid requirements, and decreases opioid-related side effects such as PONV, sedation, and urinary retention. However, NSAIDs may increase the risk of gastrointestinal and wound bleeding , decrease kidney function , and impair wound healing . There is also a concern that NSAIDs may have a detrimental effect on anastomotic healing of the gastrointestinal tract and increase the risk of anastomotic leak, although this is controversial and further research is needed. Perioperative administration of selective cyclooxygenase-2 ( COX-2) inhibitor NSAIDs likewise reduces postoperative pain and decreases both opioid consumption and opioid-related side effects, and although their use reduces the incidence of NSAID-related platelet dysfunction and gastrointestinal bleeding, the potential adverse effects of COX-2 inhibitors on kidney function remain controversial. Concerns have also been raised, primarily with rofecoxib and valdecoxib, regarding COX-2 safety for patients undergoing cardiovascular surgery. Increased cardiovascular risk associated with the perioperative use of celecoxib or valdecoxib in patients with minimal cardiovascular risk factors and undergoing nonvascular surgery is unproven. Further studies are needed to establish the analgesic efficacy and safety of COX-2 inhibitors, their clinical impact on postoperative outcomes, and their precise role in ERPs. 2-Acetaminophen (paracetamol) — Oral, rectal, and parenteral acetaminophen is a common component of multimodal analgesia. Acetaminophen’s analgesic effect is 20% to 30% less than that of NSAIDs , but its pharmacological profile is safer. Analgesic efficacy improves when the drug is administered together with NSAIDs, and it significantly reduces pain intensity and spares opioid consumption after orthopedic and abdominal surgery. However, acetaminophen may not reduce opioid-related side effects . Routine administration of acetaminophen in combination with regional anesthesia and analgesia techniques may allow NSAIDs to be reserved for control of breakthrough pain, thus limiting the incidence of NSAID-related side effects. 3. Gabapentinoids — Oral gabapentin and pregabalin given as a single dose preoperatively have been shown to decrease postoperative pain and opioid consumption in the first 24 h following surgery. There is debate about the dose and duration of perioperative use of these drugs , and whether they may potentially alter the incidence of chronic pain after surgery. Common side effects include sedation and dizziness, especially in elderly patients . 4. N -methyl-D-aspartate (NMDA) receptor antagonists — Ketamine : Perioperative low-dose ketamine (bolus, infusion) has been associated with significant reduction in pain, opioid consumption, and PONV. Ketamine has also been shown to be of particular benefit in patients on chronic opioids. Magnesium: Magnesium may also reduce postoperative pain and opioid consumption, although the optimal dosing is uncertain. Side effects include hypotension and potentiation of neuromuscular blockade. 5. Intravenous lidocaine — Intravenous lidocaine infusion analgesia has recently increased in popularity because there is good evidence to support its use as a component of multimodal analgesia. In major abdominal surgery, it is associated with faster return of bowel function and decreased hospital length of stay. Continuous cardiovascular monitoring is frequently advocated for patients receiving intravenous lidocaine, and therefore its use is currently limited to settings such as the PACU, ICU , or a monitored hospital ward. However, several centers have developed and implemented perioperative protocols to safely use intravenous lidocaine on surgical wards without continuous cardiovascular monitoring. ** fairly new technique , Mesenchymal stem cells s cavenging nanomaterials facilitates the elimination of pro-inflammatory cytokines and ROS in microglia and ameliorates allodynia . Which are a cause of development of neuropathic pain . MSCs are multipotent stem cells, multipotent progenitor cells, or marrow stromal cells found in the bone marrow, lungs, adipose tissue, and other body tissues. MSCs have the ability to differentiate into osteogenic,